JP3638832B2 - Cosmetic and / or dermatological composition comprising at least one mulberry extract, at least one seaweed extract and at least one salicylic acid derivative - Google Patents

Cosmetic and / or dermatological composition comprising at least one mulberry extract, at least one seaweed extract and at least one salicylic acid derivative Download PDF

Info

Publication number
JP3638832B2
JP3638832B2 JP28724899A JP28724899A JP3638832B2 JP 3638832 B2 JP3638832 B2 JP 3638832B2 JP 28724899 A JP28724899 A JP 28724899A JP 28724899 A JP28724899 A JP 28724899A JP 3638832 B2 JP3638832 B2 JP 3638832B2
Authority
JP
Japan
Prior art keywords
extract
composition
skin
hair
salicylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP28724899A
Other languages
Japanese (ja)
Other versions
JP2000119127A (en
Inventor
フィリップ・トゥザン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of JP2000119127A publication Critical patent/JP2000119127A/en
Application granted granted Critical
Publication of JP3638832B2 publication Critical patent/JP3638832B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11Encapsulated compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216Solid or semisolid forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/06Emulsions
    • A61K8/066Multiple emulsions, e.g. water-in-oil-in-water
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • A61K8/375Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/08Preparations for bleaching the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures

Abstract

A cosmetic or dermatological composition, comprising:in combination, at least one extract of mulberry or an active substance isolated from the extract, at least one extract of skullcap or an active substance isolated from the extract and at least one salicylic acid derivative or salt thereof.

Description

【0001】
【発明の属する技術分野】
本発明は、少なくとも1のクワの抽出物又はその抽出物から分離した活性物質、少なくとも1のタツナミソウの抽出物又はその抽出物から分離した活性物質、及び、少なくとも1のサリチル酸誘導体の組合せを含む化粧用及び/又は皮膚科学用組成物に関する。本発明はまた、皮膚の美白(whitening)又は脱色、頭髪及び/又は他の毛髪の脱色、又は皮膚の色素沈着マークのトリートメントの目的によって、顔及び/又は身体の皮膚に局部適用することによる上記組成物の使用にも関する。
【0002】
【従来の技術】
ヒトの皮膚の色は、多くの異なるファクター、特に、その年の季節、人種及び性別に基づき、且つそれはメラノサイトによって生産されたメラニンの濃度と性質によって大部分は決定される。加えて、その寿命の異なる期間で、ある種の個人では皮膚に対して異質性を与える、皮膚上、とりわけ手の上に、暗部及び/又はより着色したシミ(marks)が発現する。これらのシミは、皮膚の表面で偏在したケラチノサイトにおけるメラニンの大きな濃度のためでもある。
【0003】
同様に、頭髪と他の毛髪の色は、メラニンによる;頭髪と他の毛髪が暗色である場合、ある人々はそれを明色とすることを望む。これは特に、それが暗色である場合よりも、それが明色である場合の方がより目立たない毛髪のために特に有効である。
【0004】
皮膚、頭髪及び他の毛髪の色素沈着の形成、即ちメラニン形成のメカニズムは、特有な複合化及び以下の主要な段階を概略的に含む:
チロシン→ドーパ→ドーパキノン→ドーパクロム→メラニン。
【0005】
チロシナーゼは、この反応の進行に含まれる必須の酵素である。特にそれは、そのヒドロキシラーゼ活性のためにドーパ(ジヒドロキシフェニルアラニン)へのチロシンの変換の反応を、及びそのオキシダーゼ活性のためにドーパキノンへのドーパの変換の反応を触媒する。このチロシナーゼは、ある種の生物学的因子の作用の下で、それが成熟形である場合にのみ作用する。
【0006】
その物質は、もしそれがメラニン生成の生起において表皮のメラノサイトの活力に直接作用するならば、及び/又はもしそれが、メラニン生成において含まれる酵素の一つを抑制することによって又はメラニンの合成鎖における、その鎖を阻止することができ且つ脱色を確保する、1つの化合物の構造的類似体として介在されるようになることによってのいずれか一方の、メラニンの生合成における工程の一つに干渉するならば、脱色されるものとして認識される。
【0007】
脱色剤として最も慣習的に使用される物質は、とりわけヒドロキノンとその誘導体、特に、ヒドロキノンモノメチルエーテルとモノエチルエーテルのようなそれのエーテルである。これらの化合物が一定の有効性を有しているとしても、それらは、残念ながら、使用にあたりそれの難解な、又は一様な危険性を作り得る、それの必然的な毒性の理由から副作用無しではない。この毒性は、それがメラニン生産の基本的メカニズムにおいて、それの生物学的環境を混乱させる危険のある及び毒の生産によってそれの消去を結果的に強いる、細胞の殺傷に干渉するという事実から生じる。
【0008】
かくして、ヒドロキノンは、顕著な刺激剤であり、メラノサイトに対する細胞毒である化合物であり、且つこの化合物の全体的な又は部分的な置換体は、多くの著者によって考察されている。
【0009】
メラニン生成メカニズムにおいて何れかの関わり合いを有しておらず、しかしそれの活性化を防止することによってチロシナーゼの上流に作用し、且つかなり毒性の劣る物質が探し求められている。
【0010】
良好な有効性の無害の局部脱色用の物質は、とりわけ、妊娠中("pregnancy mask"又は肝斑)又はエストロプロゲステーティブ避妊(oestroprogestative contraception)において生じる突発性黒皮症のようなメラノサイト高度活性化により介在される局部高度色素沈着、化学線ほくろとして知られる老人性色素沈着マークのような良性のメラノサイトの高度活性化及び増殖によって介在される局在化した高度色素沈着、光過敏症及び外傷後の瘢痕形成による偶発的な高度色素沈着又は脱色、同様に白斑のようなある種の白化を治療するためのものが探し求められている。損傷した皮膚に再色素沈着の能力を欠いている後者のために(より白い外見の皮膚を与える傷跡の結果になる瘢痕形成、及び白斑のために可能性のある)、残りの通常の皮膚のエリアの脱色は、全体的に均一な白色の色調を皮膚に与えるために有効とされる。
【0011】
かくして、ヒトの皮膚、頭髪及び/又は他の毛髪のための、周知の化合物の欠点を有さない、即ち、非刺激性、非毒性及び/又は皮膚に対して非アレルギー性で且つ組成物中で安定な、各種の美白剤が提案されている。
【0012】
例えば、欧州特許出願公開EP-A-0,747,043は、美白又は脱色用組成物において、チロシナーゼ活性のインヒビターとしてアルキルサリチル酸誘導体の使用を記載する。米国特許第5,580,549号はまた、皮膚異常変色を治療するために、高い濃度での又は他の脱色剤との組み合わせにおいて、アルキル及びアルコキシサリチル酸誘導体の使用を記載する。
【0013】
樹皮の抽出物、クワ(mulberry)の根又は桑白皮の浸出液から得られた、チロシナーゼの活性を抑制する化合物を有効成分として含む脱色化粧用組成物もまた、C.A. Essential Oils, Cosmetics, vol. 88, 1978, 227頁、abstract 88:65874zまたはJP-A-50 135,236から周知である。
【0014】
それの一部のために、特開平6-107,532号は、メラニン生成を抑制することによって色素沈着マークを予防し且つ治療するための化粧品組成物に関し、該組成物は、Scutellaria baicalensis(skullcap,タツナミソウ)の根の抽出物及びクワの樹皮の抽出物を含む1又はそれ以上の抽出物の0.001から20重量%、及び紫外線吸収剤及び/又は紫外線散乱剤の0.001から30重量%とを含む。
【0015】
【発明が解決しようとする課題】
しかしながら、上述した組成物よりもより有効であり、同時に良好に耐性化されている脱色用又は美白用組成物の必要性がある。
【0016】
ここに、本出願人は、クワ及びタツナミソウの抽出物とサリチル酸誘導体の組み合わせが、これらの化合物の有効性を驚くほど高めることを知見している。換言すれば、組み合わせにおいて使用したこれら3つの化合物は、皮膚、頭髪又は他の毛髪の美白又は脱色において相乗効果を生じるようにそれの効果を互いに増強する。
【0017】
【課題を解決するための手段】
かくして、本発明の主題は、少なくとも1のクワの抽出物又はその抽出物から分離した活性物質、少なくとも1のタツナミソウの抽出物又はその抽出物から分離した活性物質、及び式(I):
【化3】

Figure 0003638832
[式中:Rは、水素原子又は、飽和又は不飽和、直鎖、分枝又は環状脂肪族、アルコキシ、エステル又はケトキシ鎖を表し、これらの鎖は2から22までの炭素原子を含み、且つハロゲン原子、トリフルオロメチル基及び遊離形の又は1から6までの炭素原子を含む酸により、又は遊離の又は1から6までの炭素原子を含む低級アルコールによりエステル化されたその他のカルボキシル官能基によりエステル化されたヒドロキシル基から選択される少なくとも1の置換基によって置換され得る;及びR’は、ヒドロキシル基又は式:
【化4】
Figure 0003638832
(式中、R1は、1から18までの炭素原子を含む飽和又は不飽和の脂肪族基である)
のエステル官能基を表す]
のサリチル酸誘導体又はその誘導体の塩との組合せを含む、化粧用及び/又は皮膚科学用組成物である。
【0018】
【発明の実施の形態】
好ましくは、上記の基Rは、少なくとも4つの炭素原子を含む。それは例えば、4から11までの炭素原子を含む飽和した直鎖のアルキル又はアルコキシ基から形成される。
【0019】
有利には、サリチル酸誘導体は、サリチル酸、5-n-オクタノイルサリチル酸、5-n-デカノイルサリチル酸及び5-n-ドデカノイルサリチル酸から選択され、特に5-n-オクタノイルサリチル酸である。
【0020】
該サリチル酸誘導体はまた、これらの酸の塩、特に塩基との塩化により得られた塩とされ得る。
【0021】
本発明に従うサリチル誘導体を塩化することができる塩基としては、アルカリ金属水酸化物(水酸化ナトリウムと水酸化カリウム)又は水酸化アンモニウムのような無機塩基又は、更に良好には有機塩基を挙げることができる。
【0022】
好ましくは、両性の塩基、即ちアニオン性とカチオン性の官能基の両方を有する塩基が、サリチル酸誘導体を塩化するのに使用される。
【0023】
両性塩基は、第一級、第二級、第三級又は環式の有機アミン、およびとりわけアミノ酸とすることができる。両性塩基の実例としては、グリシン、リシン、アルギニン、タウリン、ヒスチジン、アラニン、バリン、システイン、トリヒドロキシメチルアミノメタン(TRISTA)及びトリエタノールアミンを挙げることができる。これらの塩基は、5と7の間にまで該エマルジョンのpHを持ってくるのに十分な、及びかくして皮膚のpHに近接した量において使用される。これは、皮膚についての本発明に従う組成物の非常に大きな和合性を生じることになる。
【0024】
上述したサリチル酸誘導体の他、本発明に従う組成物は、クワの抽出物を、有利には、モルス・アルバ(Morus alba)の根の抽出物、又はその抽出物から分離した物質、好ましくはクワノン(kuwanone)又はそれの誘導体を含む。クワノンEを分離するためのプロセスは、例えば、Chemical Abstracts, vol.89, 1978, abstract 89:211925f中に及びHeterocycles, vol. 9, No. 9, 1978中に記載される。
【0025】
該組成物はまた、タツナミソウの抽出物を、有利にはスクテラリア・バイカレンシス(Scutellaria baicalensis)の根の抽出物、又はそのような抽出物から分離した物質、好ましくはバイカリン(baicaline)を含む。
【0026】
上述した抽出物は、当該分野において当業者に周知のいずれかの抽出方法に従って、水性の、アルコール性の又は有機溶媒を用いる抽出によって調製することができる。
【0027】
用語「水性溶媒」は、全体的に又は部分的に水からなるいずれかの溶媒を意味する。水自体、いずれかの比率での水-アルコール溶媒又は水といずれかの比率でのプロピレングリコール又はブチレングリコールのような別な化合物とからなる溶媒を挙げることができる。
【0028】
アルコール性溶媒の中で特に挙げることができるは、エタノールである。
【0029】
水-アルコール溶媒による抽出によって得られた、有利には50%の水と48.5-49.5%ブチレングリコール中に0.5-1.5%活性物質を含んでいる植物の抽出物を使用することが本発明に好適である。
【0030】
本発明に従い使用される調製方法に関わりなく、保存性及び/又は安定性を促進することを目指す次のステップは、抽出物の実際の性質をこれが修正することなしに加入され得る。かくして、例えば、得られた抽出物は、いずれかの標準的な凍結乾燥法によって凍結乾燥され得る。かくて得られた使用することができる粉末は、使用の前に適当な溶媒と直接又は何か他の方法で混合される。
【0031】
本発明に従う組成物中に含まれるサリチル酸誘導体と、クワ及びタツナミソウの抽出物の量は、望まれる美白又は脱色効果に明らかに基づいており、且つ広い範囲内でその結果として変化し得る。一つの好適な実施態様において、本発明に従う組成物は、組成物の全重量に対して、0.1から5重量%までの、有利には1から2重量%までのサリチル酸誘導体、及び0.1から20重量%まで、有利には0.5から1.5重量%までのクワ及びタツナミソウの抽出物を含む。
【0032】
本発明に従う組成物は、局部使用(topical use)のために好適であり、かくして化粧品用又は皮膚科用に許容される媒体(medium)、即ち、皮膚、頭髪又は他の毛髪と和合可能である媒体を含む。
【0033】
本発明の組成物は、局部適用、特に水性、水-アルコール性又は油性溶液、水性又は油性ゲル、液状、ペースト状又は固形の無水製品、小球状として水相中に油の分散物、それはこれら粒子がナノ球体及びナノカプセルのようなポリマーナノ粒子、または更に良好にはイオン性及び/又は非イオン型の脂質ベシクルとされることを可能にする、に通常的に使用されるいずれかの製薬上の形態とすることができる。
【0034】
この組成物は、相対的に流体とすることができ、且つ白色又は着色したクリーム、軟膏、乳液、ローション、漿液、ペースト、またはフォーム(foam)の外観とし得る。それは、任意に、エアゾルの形態において皮膚又は毛髪に適用され得る。それはまた、例えばスティックの形のような固形の形態とされ得る。それは、ケア用製品として及び/又はメークアップ用製品ともされ得る。
【0035】
周知の手法において、本発明の組成物は、親水性又は親油性ゲル化剤、親水性又は親油性活性剤、保存料、酸化防止剤、溶媒、香料、フィラー、サンスクリーン、顔料、脱臭剤及び染料のような、化粧品及び皮膚科学の分野において通常使用される佐剤(adjuvant)をも含み得る。これら各種の佐剤の量は、考慮される分野において通常的に使用される量とされ、例えば組成物の全重量の0.01から20%とされる。それの性質に従って、これら佐剤は、脂質相中に、水相中に、脂質ベシクル中に及びナノ粒子中に混入され得る。
【0036】
言うまでもなく、該組成物に加えられ得る活性又は非活性化合物が、本発明の望まれる目的と矛盾することなしに選択されるであろうことは、当業者に自明であろう。
【0037】
本発明の組成物がエマルジョンである場合、脂質相の比率は、組成物の全重量に対して、5から80重量%、好ましくは5から50重量%の範囲とし得る。エマルジョン形態において組成物中に使用される油、乳化剤及び共乳化剤は、考慮される分野において通常的に使用されるそれらから選択される。乳化剤と共乳化剤は、該組成物の全重量に対して0.3から30重量%まで、好ましくは0.5から20重量%までの範囲の比率において組成物中に存在させる。
【0038】
本発明において使用することができる油は、鉱油(液状石油)、植物由来の油(アボカド油、大豆油)、動物由来の油(ラノリン)、合成油(パーヒドロスクアレン)、シリコーン油(パーフルオロポリエーテル)を挙げることができる。脂肪アルコール(セチルアルコール)、脂肪酸とワックス(カルナウバロウ、オゾケライト)もまた、脂肪物質として使用され得る。
【0039】
本発明において使用することができる乳化剤と共乳化剤は、例えば、PEG-20ステアラートのようなポリエチレングリコールの脂肪酸エステル、及びステアリン酸グリセリルのようなグリセリンの脂肪酸エステルを挙げることができる。
【0040】
親水性ゲル化剤としては、特に、カルボキシビニルポリマー(カーボマー(carbomers))、アクリラート/アルキルアクリラートコポリマーのようなアクリル酸コポリマー、ポリアクリルアミド、ポリサッカリド、天然ガム及び粘度を挙げることができ、且つ親油性ゲル化剤としては、ベントンのような変性粘度、脂肪酸の金属塩、疎水性シリカとポリエチレンを挙げることができる。
【0041】
ポリオール、ビタミン、角質溶解剤及び/又は剥離剤、抗炎症剤、鎮静剤及びそれらの混合物は、活性剤として個々に使用され得る。コウジ酸及びヒドロキノンとその誘導体のような他の脱色剤もまた、本発明に従う組成物に添加することができ、それはより少ない投薬量でこれらの剤を使用することを可能にする。それらが和合しない場合、少なくとも幾つかの活性剤は、組成物中で互いにそれらが分離するように、小球体、特にイオン性又は非イオン性ベシクル及び/又はナノ粒子(ナノカプセル及び/又はナノ球体)の中に混入され得る。
【0042】
ベンゼン-1,4-ビス(3-メチリデン-10-カンファースルホン酸)、α-シアノ-β,β-ジフェニルアクリル酸2-エチルヘキシル又はオクトクリレン、ブチルメトキシジベンゾイルメタン、メトキシケイ皮酸オクチル及び/又は酸化チタン又は酸化亜鉛のような親水性又は親油性の性質の紫外線スクリーニング剤もまた、これらの組成物中に使用され得る。
【0043】
これらの組成物は、特に、顔用、手用又は身体用の保護、トリートメント又はケアクリーム、ケア又は保護用のボディ乳液、スキンケア又はスキントリートメント用のローション、ゲル又はムース、クレンジング又は殺菌用ローション、浴用組成物、ファンデーション及び着色用クリームを構成する。後者のケースにおいて、該組成物は顔料を含む。
【0044】
上述した組成物は、ヒトの皮膚の脱色及び/又は美白用、皮膚の色素沈着マークの除去用及び/又は頭髪及び/又は他の毛髪の脱色用又はチロシナーゼの活性化及び/又はメラニン合成の抑制のために使用され得る。
【0045】
かくして、本発明は、ヒトの皮膚の脱色及び/又は美白のため及び/又は皮膚の色素沈着マークの除去のため及び/又は頭髪及び/又は他の毛髪の脱色のために本発明に従う組成物を皮膚又は毛髪に適用することを含む美容的な方法に関する。
【0046】
本発明は、以下の実施例の補助によって現に説明されるであろう。その濃度は重量%として与えられる。
【0047】
【実施例】
実施例1 −組成物の調製
以下の組成物を調製した:
Figure 0003638832
【0048】
相Aは、相Bと同じく、完全に溶解するまで75℃に加熱される。相Aは、微細で均質なエマルジョンが得られるまで、撹拌しつつ、相B中に導入される。相Cは、40℃で水の中に撹拌しつつ均質化し、次いで混合物A+B内に40℃で撹拌しつつ導入される。相Dは、40℃で導入され、撹拌しつつ分散した。
【0049】
得られた流体は、撹拌しつつ冷却した。
【0050】
脱色特性を持った流体エマルジョンが得られた。
【0051】
実施例2−実施例1の組成物の脱色効果の評価
実施例1に従う組成物の脱色活性が、製造を維持したヒトの皮膚のモデルで実証された。
【0052】
これを行うため、フォトタイプIV(phototype IV)のヒトの皮膚のサンプルを、形成外科的に得た。その皮膚フラグメントは、器官培養によってエクスビボで製造を維持し、即ち、それは懸濁した培養ウェル状の懸濁した挿入物中に配され且つそのウェルの底に置かれた培地によって生存を維持した。その培地は、週に3度、リフレッシュされる。
【0053】
以下の生産物が、21日間、週に5日、2mg/cm2の皮膚の割合で、上記フラグメントに一日一度、適用される:
生産物A: 賦形剤
生産物B: 賦形剤+5-n-オクタノイルサリチル酸の0.5%
生産物C: 賦形剤+植物抽出物(クワ+タツナミソウ)の1%
生産物D: 賦形剤+5-n-オクタノイルサリチル酸の0.5%+植物抽出物の1%(実施例1に従う組成物)
比較の目的のため、未処理皮膚フラグメントもまた、同じ条件下で生存を維持した。
【0054】
21日後、メラニンの顆粒を含んでいる基底細胞(ケラチノサイト及びメラノサイト)のパーセンテージの定量的な評価は、ヘマルメオシン(Fontana法)による染色の後、+40倍で、5つの視野について、光学顕微鏡によって組織学的に実行される。
【0055】
細胞の3つのカテゴリーが計測される:
スコア1:わずかに着色した又は着色無しの細胞
スコア2:適度に着色した細胞、即ち適度のメラニン含量を持った細胞(メラニンの散乱した顆粒、均一でない堆積)
スコア3:高度に着色した細胞、即ちメラニンの大きい含量を持つ細胞(細胞の細胞質の半分よりも多く均一な堆積物で覆われている)。
【0056】
その結果は、以下の表1中に示される。
【表1】
Figure 0003638832
【0057】
メラニン指数(MI)は、式(i):
MI=1×(スコア1)+2×(スコア2)+3×(スコア3) ……(i)
に従い、このカウントから算出した。
【0058】
この指数から、メラニンの抑制のパーセンテージを、以下の式(ii)に従って計算することができる:
抑制%=[(MI(Te)−MI(Tr))/MI(Te)]×100 ……(ii)
(式中:MI(Te)は未処理の皮膚のメラニンインデックスを表す、
MI(Tr)は試験した生産物A,B,C又はDで処理した皮膚のメラニン指数を表す)。
【0059】
その結果は、以下の表2中に示される。
【表2】
Figure 0003638832
【0060】
未処理の皮膚と、生産物A,B及びCで処理した皮膚の間に、容易に評価できる差はない。
【0061】
一方、未処理の皮膚又は生産物A,B及びCで処理した皮膚に対して、本発明に従う組成物は、高度に着色した細胞の数を有意に減少し、中程度に着色した細胞の数を増加し、かくして16%のメラニンの抑制の度合を得ることを可能にした。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a cosmetic composition comprising a combination of at least one mulberry extract or an active substance isolated from the extract, at least one extract of sea cucumber or an active substance isolated from the extract, and at least one salicylic acid derivative. And / or dermatological compositions. The present invention also relates to the above by applying locally to the skin of the face and / or body, depending on the purpose of whitening or depigmenting the skin, depigmenting the hair and / or other hair, or pigmentation marks on the skin. It also relates to the use of the composition.
[0002]
[Prior art]
The color of human skin is based on many different factors, in particular the season, race and sex of the year, which is largely determined by the concentration and nature of the melanin produced by the melanocytes. In addition, during different periods of their life, dark and / or more colored marks appear on the skin, especially on the hands, which give certain skin heterogeneity in certain individuals. These stains are also due to the large concentration of melanin in keratinocytes ubiquitous on the surface of the skin.
[0003]
Similarly, the color of the hair and other hair is due to melanin; if the hair and other hair are dark, some people want it to be light. This is particularly effective for hair that is less noticeable when it is lighter than when it is darker.
[0004]
The mechanism of pigmentation of the skin, head hair and other hairs, i.e. melanogenesis, schematically includes a specific complexation and the following main steps:
Tyrosine → Dopa → Dopaquinone → Dopachrome → Melanin.
[0005]
Tyrosinase is an essential enzyme involved in the progress of this reaction. In particular, it catalyzes the reaction of tyrosine conversion to dopa (dihydroxyphenylalanine) for its hydroxylase activity and the reaction of dopa conversion to dopaquinone for its oxidase activity. This tyrosinase acts only when it is in its mature form under the action of certain biological factors.
[0006]
The substance may have a direct effect on the vitality of epidermal melanocytes in the occurrence of melanogenesis and / or if it inhibits one of the enzymes involved in melanogenesis or the synthetic chain of melanin. Interfering with one of the steps in the biosynthesis of melanin, either by intervening as a structural analog of one compound that can block the chain and ensure decolorization If so, it will be recognized as decolorized.
[0007]
The substances most commonly used as depigmenting agents are especially hydroquinone and its derivatives, in particular its ethers such as hydroquinone monomethyl ether and monoethyl ether. Even though these compounds have a certain effectiveness, they unfortunately have no side effects because of their inevitable toxicity, which can create their esoteric or uniform risks in use. is not. This toxicity arises from the fact that it interferes with cell killing in the basic mechanism of melanin production, which can perturb its biological environment and constrains its elimination by the production of poisons .
[0008]
Thus, hydroquinone is a prominent stimulant, a compound that is a cytotoxin for melanocytes, and the total or partial substitution of this compound has been discussed by many authors.
[0009]
There is a need for substances that do not have any involvement in the mechanism of melanin production but act upstream of tyrosinase by preventing its activation and are much less toxic.
[0010]
Good-efficiency harmless local depigmenting substances are among others highly active melanocytes such as idiopathic melanosis that occurs during pregnancy ("pregnancy mask" or melasma) or oestroprogestative contraception Localized hyperpigmentation, photosensitivity and trauma mediated by local hyperpigmentation mediated by catabolism, hyperactivation and proliferation of benign melanocytes such as senile pigmentation marks known as actinic moles There is a need to seek to treat incidental hyperpigmentation or bleaching due to subsequent scar formation as well as certain types of whitening such as vitiligo. Because of the latter, which lacks the ability of repigmentation to damaged skin (possibly due to scar formation resulting in scars that give the skin a whiter appearance, and vitiligo), the remaining normal skin Decolorization of the area is effective to give the skin a uniform white tone throughout.
[0011]
Thus, it does not have the disadvantages of known compounds for human skin, hair and / or other hair, ie is non-irritating, non-toxic and / or non-allergenic to the skin and in the composition Various types of whitening agents have been proposed.
[0012]
For example, European Patent Application Publication EP-A-0,747,043 describes the use of alkylsalicylic acid derivatives as inhibitors of tyrosinase activity in whitening or bleaching compositions. US Pat. No. 5,580,549 also describes the use of alkyl and alkoxy salicylic acid derivatives at high concentrations or in combination with other depigmenting agents to treat abnormal skin discoloration.
[0013]
Decoloring cosmetic compositions obtained from bark extracts, mulberry root or mulberry bark exudates containing compounds that inhibit tyrosinase activity as active ingredients are also CA Essential Oils, Cosmetics, vol. 88, 1978, p. 227, abstract 88: 65874z or JP-A-50 135,236.
[0014]
To that end, JP-A-6-107,532 relates to a cosmetic composition for preventing and treating pigmentation marks by inhibiting melanogenesis, said composition comprising Scutellaria baicalensis (skullcap, sea bream). ) Root extract and mulberry bark extract and from 0.001 to 20% by weight of the extract and from 0.001 to 30% by weight of the UV absorber and / or UV scattering agent.
[0015]
[Problems to be solved by the invention]
However, there is a need for decolorizing or whitening compositions that are more effective than the above-described compositions and at the same time are well tolerated.
[0016]
Here, the Applicant has found that the combination of mulberry and seaweed extracts and salicylic acid derivatives surprisingly increases the effectiveness of these compounds. In other words, these three compounds used in the combination enhance their effects on each other so as to produce a synergistic effect in the whitening or bleaching of the skin, head hair or other hair.
[0017]
[Means for Solving the Problems]
Thus, the subject of the present invention is at least one mulberry extract or an active substance separated from the extract thereof, at least one extract of the seaweed or an extract thereof and formula (I):
[Chemical 3]
Figure 0003638832
[Wherein R represents a hydrogen atom or a saturated or unsaturated, linear, branched or cycloaliphatic, alkoxy, ester or ketoxy chain, these chains containing from 2 to 22 carbon atoms, and By halogen atoms, trifluoromethyl groups and other carboxyl functional groups esterified with free or acids containing 1 to 6 carbon atoms, or with free or lower alcohols containing 1 to 6 carbon atoms May be substituted by at least one substituent selected from an esterified hydroxyl group; and R ′ may be a hydroxyl group or the formula:
[Formula 4]
Figure 0003638832
(Wherein R 1 is a saturated or unsaturated aliphatic group containing from 1 to 18 carbon atoms)
Represents an ester functional group of
A cosmetic and / or dermatological composition comprising a salicylic acid derivative of or a combination thereof with a salt thereof.
[0018]
DETAILED DESCRIPTION OF THE INVENTION
Preferably, the above group R contains at least 4 carbon atoms. It is formed, for example, from a saturated linear alkyl or alkoxy group containing from 4 to 11 carbon atoms.
[0019]
Advantageously, the salicylic acid derivative is selected from salicylic acid, 5-n-octanoylsalicylic acid, 5-n-decanoylsalicylic acid and 5-n-dodecanoylsalicylic acid, in particular 5-n-octanoylsalicylic acid.
[0020]
The salicylic acid derivative can also be a salt of these acids, in particular a salt obtained by chlorination with a base.
[0021]
Bases that can salify salicyl derivatives according to the present invention include inorganic bases such as alkali metal hydroxides (sodium hydroxide and potassium hydroxide) or ammonium hydroxide, or better still organic bases. it can.
[0022]
Preferably, amphoteric bases, ie bases having both anionic and cationic functional groups, are used to salify the salicylic acid derivative.
[0023]
Amphoteric bases can be primary, secondary, tertiary or cyclic organic amines, and especially amino acids. Examples of amphoteric bases include glycine, lysine, arginine, taurine, histidine, alanine, valine, cysteine, trihydroxymethylaminomethane (TRISTA) and triethanolamine. These bases are used in amounts sufficient to bring the pH of the emulsion to between 5 and 7, and thus close to the pH of the skin. This will result in a very great compatibility of the composition according to the invention with respect to the skin.
[0024]
In addition to the salicylic acid derivatives mentioned above, the composition according to the invention comprises a mulberry extract, advantageously a Morus alba root extract, or a material separated from the extract, preferably quanon ( kuwanone) or derivatives thereof. Processes for separating Quwanon E are described, for example, in Chemical Abstracts, vol. 89, 1978, abstract 89: 211925f and in Heterocycles, vol. 9, No. 9, 1978.
[0025]
The composition also comprises an extract of seaweed, advantageously a root extract of Scutellaria baicalensis, or a material separated from such an extract, preferably baicaline.
[0026]
The extracts described above can be prepared by extraction with aqueous, alcoholic or organic solvents according to any extraction method well known to those skilled in the art.
[0027]
The term “aqueous solvent” means any solvent consisting entirely or in part of water. Mention may be made of water itself, a water-alcohol solvent in any ratio or a solvent consisting of water and another compound such as propylene glycol or butylene glycol in any ratio.
[0028]
Among the alcoholic solvents that may be mentioned in particular is ethanol.
[0029]
It is suitable for the present invention to use a plant extract obtained by extraction with a water-alcohol solvent, preferably containing 0.5-1.5% active substance in 50% water and 48.5-49.5% butylene glycol. It is.
[0030]
Regardless of the preparation method used in accordance with the present invention, the next step aiming to promote storage and / or stability can be taken without this modifying the actual properties of the extract. Thus, for example, the resulting extract can be lyophilized by any standard lyophilization method. The powders that can be used thus obtained are mixed directly or in some other way with a suitable solvent before use.
[0031]
The amount of salicylic acid derivative and the extract of mulberry and seaweed contained in the composition according to the invention is clearly based on the desired whitening or bleaching effect and can vary as a result within a wide range. In one preferred embodiment, the composition according to the invention comprises from 0.1 to 5% by weight, preferably from 1 to 2% by weight of salicylic acid derivative, based on the total weight of the composition; 1 to 20% by weight, preferably 0.5 to 1.5% by weight of mulberry and seaweed extract.
[0032]
The composition according to the invention is suitable for topical use and is thus compatible with cosmetic or dermatologically acceptable medium, i.e. skin, hair or other hair Includes media.
[0033]
The composition of the present invention is suitable for topical application, in particular aqueous, water-alcoholic or oily solutions, aqueous or oily gels, liquid, pasty or solid anhydrous products, dispersions of oil in the aqueous phase as small spheres, which Any pharmaceutical commonly used to allow the particles to be polymeric nanoparticles such as nanospheres and nanocapsules, or better still ionic and / or non-ionic lipid vesicles The above form can be adopted.
[0034]
The composition can be relatively fluid and can have the appearance of a white or colored cream, ointment, emulsion, lotion, serum, paste, or foam. It can optionally be applied to the skin or hair in the form of an aerosol. It can also be in solid form, for example in the form of a stick. It can be made as a care product and / or as a make-up product.
[0035]
In a known manner, the composition of the present invention comprises a hydrophilic or lipophilic gelling agent, a hydrophilic or lipophilic active agent, a preservative, an antioxidant, a solvent, a fragrance, a filler, a sunscreen, a pigment, a deodorant and Adjuvants commonly used in the cosmetic and dermatological fields, such as dyes, may also be included. The amounts of these various adjuvants are those usually used in the field under consideration, for example 0.01 to 20% of the total weight of the composition. Depending on their nature, these adjuvants can be incorporated in the lipid phase, in the aqueous phase, in lipid vesicles and in nanoparticles.
[0036]
Of course, it will be apparent to those skilled in the art that active or inactive compounds that may be added to the composition will be selected without conflicting with the desired purpose of the invention.
[0037]
When the composition according to the invention is an emulsion, the proportion of the lipid phase can range from 5 to 80% by weight, preferably from 5 to 50% by weight, relative to the total weight of the composition. The oils, emulsifiers and coemulsifiers used in the composition in emulsion form are selected from those commonly used in the field under consideration. The emulsifier and co-emulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, preferably from 0.5 to 20% by weight relative to the total weight of the composition.
[0038]
Oils that can be used in the present invention include mineral oil (liquid petroleum), plant-derived oil (avocado oil, soybean oil), animal-derived oil (lanolin), synthetic oil (perhydrosqualene), silicone oil (perfluorocarbon). Polyether)). Fatty alcohols (cetyl alcohol), fatty acids and waxes (carnauba wax, ozokerite) can also be used as fatty substances.
[0039]
Examples of the emulsifier and coemulsifier that can be used in the present invention include a fatty acid ester of polyethylene glycol such as PEG-20 stearate and a fatty acid ester of glycerin such as glyceryl stearate.
[0040]
Hydrophilic gelling agents can include, among others, carboxyvinyl polymers (carbomers), acrylic acid copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and viscosities, and Examples of the lipophilic gelling agent include modified viscosity such as Benton, metal salts of fatty acids, hydrophobic silica and polyethylene.
[0041]
Polyols, vitamins, keratolytics and / or exfoliants, anti-inflammatory agents, sedatives and mixtures thereof can be used individually as active agents. Other depigmenting agents such as kojic acid and hydroquinone and their derivatives can also be added to the composition according to the invention, which makes it possible to use these agents in smaller dosages. If they are not compatible, at least some of the active agents may be small spheres, especially ionic or non-ionic vesicles and / or nanoparticles (nanocapsules and / or nanospheres) so that they separate from each other in the composition. ).
[0042]
Benzene-1,4-bis (3-methylidene-10-camphorsulfonic acid), α-cyano-β, β-diphenylacrylate 2-ethylhexyl or octocrylene, butylmethoxydibenzoylmethane, octyl methoxycinnamate and / or Ultraviolet screening agents of hydrophilic or lipophilic nature such as titanium oxide or zinc oxide can also be used in these compositions.
[0043]
These compositions include, in particular, facial, hand or body protection, treatment or care cream, care or protective body milk, skin care or skin treatment lotion, gel or mousse, cleansing or disinfecting lotion, Make up bath compositions, foundations and creams for coloring. In the latter case, the composition comprises a pigment.
[0044]
The composition described above is intended for depigmentation and / or whitening of human skin, removal of pigmentation marks on skin and / or depigmentation of hair and / or other hair or activation of tyrosinase and / or inhibition of melanin synthesis. Can be used for.
[0045]
Thus, the present invention provides a composition according to the invention for the depigmentation and / or whitening of human skin and / or for the removal of pigmentation marks on the skin and / or for depigmentation of the hair and / or other hair. It relates to a cosmetic method comprising applying to the skin or hair.
[0046]
The invention will now be explained with the aid of the following examples. The concentration is given as weight percent.
[0047]
【Example】
Example 1-Preparation of the composition The following composition was prepared:
Figure 0003638832
[0048]
Phase A, like Phase B, is heated to 75 ° C. until completely dissolved. Phase A is introduced into phase B with stirring until a fine and homogeneous emulsion is obtained. Phase C is homogenized with stirring in water at 40 ° C. and then introduced into mixture A + B with stirring at 40 ° C. Phase D was introduced at 40 ° C. and dispersed with stirring.
[0049]
The resulting fluid was cooled with stirring.
[0050]
A fluid emulsion with decolorizing properties was obtained.
[0051]
Example 2-Evaluation of the depigmenting effect of the composition of Example 1 The depigmenting activity of the composition according to Example 1 was demonstrated in a model of human skin maintained in production.
[0052]
To do this, samples of human skin of phototype IV were obtained surgically. The skin fragment was maintained ex vivo by organ culture, i.e. it was placed in a suspended insert in a suspended culture well and maintained viable by the medium placed at the bottom of the well. The medium is refreshed 3 times a week.
[0053]
The following products are applied to the fragments once a day for 21 days, 5 days a week at a rate of 2 mg / cm 2 skin:
Product A: Excipient Product B: 0.5% of excipient + 5-n-octanoylsalicylic acid
Product C: 1% of excipient + plant extract (mulberry + seaweed)
Product D: Excipient + 0.5% of 5-n-octanoylsalicylic acid + 1% of plant extract (composition according to Example 1)
For comparative purposes, the untreated skin fragment also maintained survival under the same conditions.
[0054]
After 21 days, a quantitative assessment of the percentage of basal cells (keratinocytes and melanocytes) containing melanin granules is +40 times after staining with hemalmeosin (Fontana method) and histology by light microscopy for 5 fields. Is executed automatically.
[0055]
Three categories of cells are measured:
Score 1: Slightly or unstained cells Score 2: moderately colored cells, ie cells with moderate melanin content (scattered granules of melanin, non-uniform deposition)
Score 3: Highly colored cells, ie cells with a high content of melanin (covered with more than half the cytoplasm of the cells and covered with a uniform deposit).
[0056]
The results are shown in Table 1 below.
[Table 1]
Figure 0003638832
[0057]
Melanin index (MI) is calculated using the formula (i):
MI = 1 × (score 1) + 2 × (score 2) + 3 × (score 3) (i)
And calculated from this count.
[0058]
From this index, the percentage of inhibition of melanin can be calculated according to the following equation (ii):
Suppression% = [(MI (Te) −MI (Tr)) / MI (Te)] × 100 (ii)
(Wherein MI (Te) represents the melanin index of untreated skin,
MI (Tr) represents the melanin index of skin treated with the products A, B, C or D tested).
[0059]
The results are shown in Table 2 below.
[Table 2]
Figure 0003638832
[0060]
There is no easily appreciable difference between untreated skin and skin treated with products A, B and C.
[0061]
On the other hand, for untreated skin or skin treated with products A, B and C, the composition according to the invention significantly reduces the number of highly colored cells and the number of moderately colored cells. Thus making it possible to obtain a degree of inhibition of melanin of 16%.

Claims (8)

少なくとも1のクワの抽出物又はその抽出物から分離した活性物質、少なくとも1のタツナミソウの抽出物又はその抽出物から分離した活性物質、及び - - オクタノイルサリチル酸又はその塩との組合せを含む、化粧用及び/又は皮膚科学用組成物。Includes a combination of octanoyl salicylic acid or a salt thereof - active substance isolated from at least one of the mulberry extract or extracts thereof, active substances were separated from the extract of at least one of skullcap or an extract thereof, and 5 - n , Cosmetic and / or dermatological compositions. 前記5 - - オクタノイルサリチル酸又はその塩が、組成物の全重量に対して0.1から5重量%まで濃度で存在することを特徴とする請求項記載の組成物。 The 5 - n - octanoyl salicylic acid or a salt thereof The composition of claim 1, wherein the present in a concentration of from 0.1 relative to the total weight of the composition up to 5% by weight. 前記抽出物の少なくとも1つが水-アルコール抽出物であることを特徴とする請求項1または2記載の組成物。Composition according to claim 1 or 2 , characterized in that at least one of the extracts is a water-alcohol extract. 記クワの抽出物が、モルス・アルバ(Morus alba)の根の抽出物であることを特徴とする請求項1からのいずれか1項記載の組成物。 Before Symbol extract of mulberry is Morusu alba (Morus alba) composition according to any one of claims 1 to 3, characterized in that an extract of the roots. 記タツナミソウの抽出物が、スキュテラリア・バイカレンシス(Scutellaria baicalensis)の根の抽出物であることを特徴とする請求項1からのいずれか1項記載の組成物。 Before Symbol extract of skullcap is Sukyuteraria baicalensis (Scutellaria baicalensis) composition according to any one of claims 1-4, characterized in that an extract of the roots. 組成物の全重量に対して、記抽出物のそれぞれを0.1から20重量%ま含むことを特徴とする請求項1からのいずれか1項記載の組成物。Relative to the total weight of the composition, prior SL respectively any one composition as claimed in claims 1 to 5, characterized in that it comprises until 20% by weight 0.1 extract. 化粧品用及び/又は皮膚科用に許容される媒体を含むことを特徴とする請求項1からのいずれか1項記載の組成物。The composition according to any one of claims 1 to 6 , comprising a medium acceptable for cosmetics and / or dermatology. 皮膚、頭髪及び/又は他の毛髪に請求項1からのいずれか1項記載の組成物を適用することを含むことを特徴とする、ヒトの皮膚、頭髪及び/又は他の毛髪の脱色及び/又は美白のため、治療方法を除く美容処理方法。Depigmentation of human skin , head hair and / or other hair , characterized in that it comprises applying the composition according to any one of claims 1 to 7 to the skin , head hair and / or other hair for / or whitening, cosmetic treatment process except for the method of treatment.
JP28724899A 1998-10-12 1999-10-07 Cosmetic and / or dermatological composition comprising at least one mulberry extract, at least one seaweed extract and at least one salicylic acid derivative Expired - Fee Related JP3638832B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9812747 1998-10-12
FR9812747A FR2784294B1 (en) 1998-10-12 1998-10-12 COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE WALL EXTRACT, AT LEAST ONE SCUTELLAR EXTRACT AND AT LEAST ONE SALICYLIC ACID DERIVATIVE

Publications (2)

Publication Number Publication Date
JP2000119127A JP2000119127A (en) 2000-04-25
JP3638832B2 true JP3638832B2 (en) 2005-04-13

Family

ID=9531441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP28724899A Expired - Fee Related JP3638832B2 (en) 1998-10-12 1999-10-07 Cosmetic and / or dermatological composition comprising at least one mulberry extract, at least one seaweed extract and at least one salicylic acid derivative

Country Status (11)

Country Link
US (1) US6348204B1 (en)
EP (1) EP0997140B1 (en)
JP (1) JP3638832B2 (en)
KR (1) KR100345096B1 (en)
CN (1) CN1217644C (en)
AT (1) ATE200419T1 (en)
CA (1) CA2286409C (en)
DE (1) DE69900081T2 (en)
ES (1) ES2157684T3 (en)
FR (1) FR2784294B1 (en)
TW (1) TW529956B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874463A (en) * 1994-10-24 1999-02-23 Ancira; Margaret Hydroxy-kojic acid skin peel
US20020034772A1 (en) 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
KR100374161B1 (en) * 2000-03-31 2003-03-03 주식회사 코리아나화장품 Skin care composition containing Phytosphingosine and Morus alba Extract
KR100450827B1 (en) * 2002-04-13 2004-10-01 홍영식품 주식회사 Chewing-gum Comprising the Components of Leaves of Mulberry and Process for Preparing the Same
JP2004083551A (en) * 2002-07-02 2004-03-18 Kao Corp Whitening composition
KR20050037102A (en) * 2003-10-17 2005-04-21 한국 한의학 연구원 Compositions for inhibiting obesity
US7429391B2 (en) * 2004-01-30 2008-09-30 Access Business Group International Llc Holistic composition and method for reducing skin pigmentation
FR2871061B1 (en) * 2004-06-04 2007-08-10 Coletica Sa ACTIVE PRINCIPLE CAPABLE OF INDUCING TRANSFORMATION FROM INACTIVE TGBF-LATENT TO ACTIVE TGFB
AU2005316824B2 (en) * 2004-12-17 2012-05-31 Bionovo, Inc. Method of using extracts of epimedium species
US7815949B2 (en) * 2004-12-17 2010-10-19 Bionovo, Inc. Estrogenic extracts of Morus alba and uses thereof
US20060153935A1 (en) * 2005-01-07 2006-07-13 Natalie Blahut Stabilizing salicylate compositions and method of preparation for oral and topical use
KR100675753B1 (en) 2005-01-14 2007-01-29 나드리화장품주식회사 Functional cosmetic composition
US7482029B2 (en) 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
EP1881839A4 (en) 2005-05-09 2009-05-20 Unigen Pharmaceuticals Inc Compositions of bakuchiol and methods of making the same
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
FR2894961B1 (en) * 2005-12-16 2008-05-16 Oreal USE OF CERAMIDES FOR DEPIGMENTING THE SKIN
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
CA2696304A1 (en) * 2007-08-08 2009-02-12 Bionovo, Inc. Estrogenic extracts of ligustrum lucidum ait. of the oleaceae family and uses thereof
CA2698732A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of astragalus membranaceus fisch.bge.var.mongolicus bge. of the leguminosae family and uses thereof
AU2008296176A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family and uses thereof
CA2698739A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of pueraria lobata willd. ohwi of the leguminosae family and uses thereof
WO2009033075A1 (en) 2007-09-07 2009-03-12 Bionovo. Inc. ESTROGENIC EXTRACTS OF Scuttelaria barbata D. DON OF THE LABIATAE FAMILY AND USES THEREOF
WO2009070478A2 (en) * 2007-11-19 2009-06-04 Bionovo, Inc. A process of making purified extract of scutellaria barbata d. don
CA2706326A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
WO2009067550A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Methods of detecting and treatment of cancers using scuttelaria barbata extract
US20090130101A1 (en) * 2007-11-19 2009-05-21 Bionovo, Inc. Anti-cancer therapy with an extract of scutellaria barbata
KR100949926B1 (en) * 2008-01-31 2010-03-30 주식회사 아이피어리스 Funetional cosmetic composition containing herb medicine extract, having antiphlogistic, antioxidantal, whitening and anti-microbial effect
JP2011516583A (en) * 2008-04-14 2011-05-26 バイオノボ・インコーポレーテッド Calicosin and its analogues for the treatment of estrogen receptor β-mediated diseases
CA2723403A1 (en) * 2008-05-06 2009-11-12 Bionovo, Inc. Estrogenic extracts for use in treating vaginal and vulvar atrophy
EP2294402A2 (en) * 2008-06-05 2011-03-16 Bionovo Inc. Method of quantification of multiple bioactives from botanical compositons
EP2303249A4 (en) * 2008-06-06 2012-05-30 Bionovo Inc Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
JP2012501974A (en) * 2008-09-03 2012-01-26 バイオノボ・インコーポレーテッド Methods and compositions for the treatment of cancer
EP2424555A4 (en) * 2009-04-28 2013-02-20 Bionovo Inc Method of reducing fat accumulation and inducing weight loss
US8685472B2 (en) 2010-03-01 2014-04-01 Access Business Group International Llc Skin whitening composition containing chia seed extract
US8409636B2 (en) 2010-09-29 2013-04-02 Access Business Group International Llc Chia seed extract and related method of manufacture
CN101978996B (en) * 2010-10-25 2012-01-25 中国人民解放军第三军医大学第一附属医院 Preparation method of traditional Chinese medicinal composition for preventing and treating sunburn and cream, and cream thereof
US8772252B2 (en) 2011-01-27 2014-07-08 New York University Coumarin compounds as melanogenesis modifiers and uses thereof
WO2012106551A1 (en) 2011-02-02 2012-08-09 Unigen, Inc. Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
FR2977490B1 (en) * 2011-07-07 2014-03-21 Oreal PHOTOPROTECTIVE COMPOSITION
FR3018190B1 (en) * 2014-03-06 2016-03-18 Laboratoires M&L LIGHTENING COSMETIC COMPOSITION
FR3072025B1 (en) * 2017-10-06 2019-11-01 Plant Advanced Technologies Pat RACINARY EXTRACTS OF MORUS PLANTS AND USES THEREOF
FR3098715B1 (en) * 2019-07-19 2021-12-31 Laboratoire Garancia Skin whitening cosmetic composition comprising hexylresorcinol, undecylenoyl phenylalanine and trimethoxybenzylidene pentanedione.
KR20210065583A (en) 2019-11-27 2021-06-04 주식회사 더스푼 Process for preparing milk tea with mulberry leaf
WO2021114024A1 (en) * 2019-12-09 2021-06-17 L'oreal Composition for brightening and/or whitening keratin materials

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109012A (en) * 1994-03-17 1998-09-24 Fischer Pharma Ltd Skin whitening composition comprising glycyrrhyza glabra and hydroxy acids
FR2732594B1 (en) * 1995-04-07 1997-06-06 Oreal USE OF DERIVATIVES OF SALICYLIC ACID FOR DEPIGMENTATION OF THE SKIN
JPH09227353A (en) * 1996-02-26 1997-09-02 Tsumura & Co Skin whitening cosmetic composition
US5773014A (en) * 1996-10-07 1998-06-30 Bioetica, Inc. Compositions and methods for inhibiting the formation of unwanted skin pigmentation

Also Published As

Publication number Publication date
EP0997140A1 (en) 2000-05-03
EP0997140B1 (en) 2001-04-11
CA2286409A1 (en) 2000-04-12
KR100345096B1 (en) 2002-07-24
FR2784294B1 (en) 2000-11-17
CA2286409C (en) 2006-05-16
FR2784294A1 (en) 2000-04-14
CN1217644C (en) 2005-09-07
KR20000028982A (en) 2000-05-25
JP2000119127A (en) 2000-04-25
ATE200419T1 (en) 2001-04-15
DE69900081T2 (en) 2001-08-02
US6348204B1 (en) 2002-02-19
DE69900081D1 (en) 2001-05-17
ES2157684T3 (en) 2001-08-16
CN1261528A (en) 2000-08-02
TW529956B (en) 2003-05-01

Similar Documents

Publication Publication Date Title
JP3638832B2 (en) Cosmetic and / or dermatological composition comprising at least one mulberry extract, at least one seaweed extract and at least one salicylic acid derivative
JP3023088B2 (en) Use of oxamate derivatives as depigmenting agents
JPH0812565A (en) Skin external preparation
JPH0930946A (en) Beautifying and whitening dermal preparation for external use
JPH09157153A (en) Preparation for external use for skin
JP3410870B2 (en) External preparation for skin
JPH0925212A (en) Skin preparation for external use
JP2002370962A (en) Bleaching preparation and cosmetic for preventing and improving aging of skin
JPH0925213A (en) Skin preparation for external use
JP4285939B2 (en) Topical skin preparation
JP2001172173A (en) Cosmetic composition containing n-ethyloxycarbonyl-4- aminophenol and arbutin or its derivative and/or ellagic acid or its derivative
KR100364314B1 (en) Use of unfermented honey as a depigmenting agent
JPH0971522A (en) Skin preparation for external use for lightening skin
KR100415278B1 (en) Skin whitening compositions using the Fragrance
JPH0987135A (en) Dermal preparation for external use
JPH0995420A (en) Preparation for external use for skin
JPH0920635A (en) Whitening skin preparation for external use
JPH0995436A (en) Preparation for external use for skin
JPH0920634A (en) Whitening skin preparation for external use
JPH0812564A (en) Skin external preparation
JPH0812550A (en) Skin external preparation
JPH0812557A (en) Skin external preparation
JP2005247732A (en) External preparation for skin
JPH0920636A (en) Skin preparation for external use
JP2005289922A (en) Skin care preparation fop external use for bleaching skin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20041214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050112

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080121

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090121

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090121

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100121

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110121

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110121

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120121

Year of fee payment: 7

LAPS Cancellation because of no payment of annual fees